Gerburg M. Wulf
- Oncology top 0.5%
- PARP inhibition in cancer therapy 18
- Peptidase Inhibition and Analysis 10
- HER2/EGFR in Cancer Research 10
- Cancer Immunotherapy and Biomarkers 10
- Immunology top 1%
- Molecular Biology top 1%
- Signaling Pathways in Disease 23
- Ubiquitin and proteasome pathways 8
- Cancer Research top 2%
- Cell Biology top 2%
-
- BRCA gene mutations in cancer 11
-
- Advanced Breast Cancer Therapies 11
- Co-authors
- Kun Ping LuAkihide RyoXiao Zhen ZhouYih‐Cherng LiouFutoshi SuizuYih-Cherng LiouPeter DaviesPei‐Jung Lu
- Cited by
- OncologyImmunologyMolecular Biology
- Partner nations
- United StatesGermanyChina
In The Last Decade
Gerburg M. Wulf
97 papers receiving 7.7k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 3.8k
- Immunology 2.1k
- Molecular Biology 5.6k
- Cancer Research 965
- Cell Biology 668
Countries citing papers authored by Gerburg M. Wulf
This map shows the geographic impact of Gerburg M. Wulf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerburg M. Wulf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerburg M. Wulf more than expected).
Fields of papers citing papers by Gerburg M. Wulf
This network shows the impact of papers produced by Gerburg M. Wulf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerburg M. Wulf. The network helps show where Gerburg M. Wulf may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gerburg M. Wulf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 8 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 0 | |
| 7 | 2022 | 5 | |
| 8 | 2022 | 22 | |
| 9 | 2021 | 34 | |
| 10 | 2020 | 23 | |
| 11 | 2020 | 42 | |
| 12 | 2019 | 13 | |
| 13 | 2018 | 44 | |
| 14 | 2017 | 49 | |
| 15 | 2016 | 59 | |
| 16 | 2014 | 66 | |
| 17 | 2012 | 336 | |
| 18 | 2011 | 75 | |
| 19 | 2001 | 462 | |
| 20 | 1992 | 10 |
About Gerburg M. Wulf
Gerburg M. Wulf is a scholar working on Oncology, Cancer Research and Immunology, having authored 100 papers that have together received 7.8k indexed citations. Recurring topics across this work include Signaling Pathways in Disease (23 papers), PARP inhibition in cancer therapy (18 papers), BRCA gene mutations in cancer (11 papers), Advanced Breast Cancer Therapies (11 papers), Peptidase Inhibition and Analysis (10 papers), HER2/EGFR in Cancer Research (10 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Ubiquitin and proteasome pathways (8 papers). The work is most often cited by research in Oncology (3.8k citations), Immunology (2.1k citations) and Molecular Biology (5.6k citations). Gerburg M. Wulf has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Kun Ping Lu, Akihide Ryo, Xiao Zhen Zhou, Yih‐Cherng Liou, Futoshi Suizu, Yih-Cherng Liou, Peter Davies, Pei‐Jung Lu, Greg Finn and Lewis C. Cantley.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.